teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 31 Projects Releases Packages Wiki Activity Actions 841

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Browse source 
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents 2026-03-18 17:58:51 +00:00
parent 5d95f7ea1d
commit a955c126da
2 changed files with 31 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

12
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -89,6 +89,18 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu
WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
### Additional Evidence (challenge)
*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18*
International generic competition beginning in 2026 creates price compression trajectory that contradicts the 'inflationary through 2035' timeline. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026 (Biomm + Biocon). China has 17+ generic candidates in Phase 3 with projected pricing of $40-$50/month. India patents expire March 2026. Even with US patents extending to 2031-2032, international price arbitrage and compounding pharmacy pressure will compress US prices faster than the existing claim assumes. If global prices reach $50-100/month by 2030 (5+ years before US patent expiry), the cost-effectiveness calculation flips from inflationary to cost-saving under risk-bearing payment models, especially given the multi-organ protection benefits.
### Additional Evidence (extend)
*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18*
Oral Wegovy launched January 2026 at $149-$299/month (Medicare deal: $245/month), representing 75-85% price reduction from injectable formulations. This oral formulation price compression is happening 5-6 years before US generic competition, suggesting the price trajectory may follow a two-phase decline: (1) oral formulation competition 2026-2031, (2) generic competition 2031+. The existing claim's 2035 inflection point may need revision to account for oral formulation price pressure beginning in 2026.
---
Relevant Notes:

20
inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md
View file

@ -7,9 +7,13 @@ date: 2026-02-01
domain: health
secondary_domains: [internet-finance]
format: article
status: unprocessed
status: enrichment
priority: medium
tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
processed_by: vida
processed_date: 2026-03-18
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -50,3 +54,17 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
## Key Facts
- Semaglutide US patents extend to 2031-2032
- Semaglutide Europe patents extend to 2031-2032
- Canada semaglutide patents expired January 4, 2026
- Brazil generic semaglutide competition opens March 2026
- India semaglutide patents expire March 2026
- China has 17+ generic semaglutide candidates in Phase 3 trials
- Oral Wegovy launched January 2026 at $149-$299/month
- Medicare oral Wegovy deal: $245/month
- Orforglipron (Eli Lilly non-peptide oral GLP-1) potential approval Q2 2026
- Sandoz, Apotex, Teva filed for Canadian generic semaglutide immediately after patent expiry
- Biomm + Biocon (India) preparing generic semaglutide for Brazil market